PARP抑制剂联合雄激素受体信号抑制剂治疗转移性前列腺癌:定量合成与Meta分析
该系统评价与Meta分析纳入PROPEL、MAGNITUDE和TALAPRO-2三项3期随机对照试验,共2601例转移性去势抵抗性前列腺癌患者。PARPi联合ARSI一线治疗相比安慰剂联合ARSI,影像学无进展生存期汇总风险比为0.62(95%CI 0.53-0.72),总生存期汇总风险比为0.84(95%CI 0.72-0.98)。作者认为结果支持在生物标志物未选择的mCRPC中使用ARSI联合PARPi,但在HRR功能正常肿瘤中临床相关性可能较低。
要点
- 三项3期RCT共2601例mCRPC患者纳入分析。
- PARPi联合ARSI的影像学无进展生存期汇总HR为0.62(95%CI 0.53-0.72)。
- 总生存期汇总HR为0.84(95%CI 0.72-0.98),死亡风险降低16%。
核心结论
- Meta分析结果支持在生物标志物未选择的mCRPC中使用ARSI联合PARPi方案。
- 在HRR功能正常的肿瘤中,此类联合方案临床相关性可能较低,尤其考虑到mCRPC治疗格局的变化。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE、SCOPUS和Cochrane Library数据库至2023年2月28日。
- 纳入比较PARPi联合ARSI与安慰剂联合ARSI一线治疗mCRPC的随机对照试验。
- 共纳入三项3期随机对照试验:PROPEL、MAGNITUDE和TALAPRO-2,合计2601例mCRPC患者。
- 由两名评价者独立进行筛选、数据提取和偏倚风险评估,第三名评价者评估纳入标准。
主要发现
- PROPEL和TALAPRO-2两项试验评估了PARPi联合ARSI一线治疗mCRPC的影像学无进展生存期获益,不依赖HRR状态。
- 影像学无进展生存期汇总风险比为0.62(95%CI 0.53-0.72)。
- 总生存期汇总风险比为0.84(95%CI 0.72-0.98),接受联合治疗的患者死亡风险降低16%。
局限性
- 在HRR功能正常的肿瘤中,PARPi联合ARSI的临床相关性可能较低。
- 需考虑mCRPC治疗格局的变化对联合方案临床相关性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: PARP inhibitors (PARPi) are established treatments for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency after androgen receptor signalling inhibitor (ARSI) failure. New PARPi + ARSI combinations have been tested in all comers, although their clinical relevance in HRR-proficient tumours remains uncertain. OBJECTIVE: To quantitatively synthesise evidence from randomised trials assessing the efficacy and safety of PARPi + ARSI combinations for first-line treatment of mCRPC. EVIDENCE ACQUISITION: We searched the PubMed, EMBASE, SCOPUS, and Cochrane Library databases up to February 28, 2023. Randomised controlled trials (RCTs) comparing PARPi + ARSI versus placebo + ARSI for first-line treatment of mCRPC were eligible. Two reviewers independently performed screening and data extraction and assessed the risk of bias, while a third reviewer evaluated the eligibility criteria. EVIDENCE SYNTHESIS: Overall, three phase 3 RCTs were included in the systematic review: PROPEL, MAGNITUDE, and TALAPRO-2. A total of 2601 patients with mCRPC were enrolled. Two of these trials (PROPEL and TALAPRO-2) assessed the radiographic progression-free survival benefit of PARPi + ARSI for first-line treatment of mCRPC, independent of HRR status. The pooled hazard ratio was 0.62 (95% confidence interval 0.53-0.72). The pooled hazard ratio for overall survival was 0.84 (95% confidence interval 0.72-0.98), indicating a 16% reduction in the risk of death among patients who received the combination. CONCLUSIONS: Results from this meta-analysis support the use of ARSI + PARPi combinations in biomarker-unselected mCRPC. However, such combinations might be less clinically relevant in HRR-proficient cancers, especially considering the change in treatment landscape for mCRPC. PATIENT SUMMARY: We looked at outcomes from trials testing combinations of two classes of drugs (PARP inhibitors and ARSI) in advanced prostate cancer. We found that these combinations seem to work regardless of gene mutations identified as biomarkers of response to PARP inhibitors when used on their own.
引用
- Messina C, Giunta EF, Signori A, et al. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. Eur Urol Oncol. 2023. PMID: 37574390. doi:10.1016/j.euo.2023.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。